SCYNEXIS, Inc. Interest Expense Nonoperating
SCYNEXIS, Inc. (SCYX) reported Interest Expense Nonoperating of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-10
- SCYNEXIS, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $0.00.
- SCYNEXIS, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. interest expense nonoperating for fiscal 2025 was $173.00K, a 79.11% decline from fiscal 2024.
- SCYNEXIS, Inc. interest expense nonoperating for fiscal 2024 was $828.00K, a 73.55% decline from fiscal 2023.
- SCYNEXIS, Inc. interest expense nonoperating for fiscal 2023 was $3.13M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-10 | $0.00 10-Q · filed 2026-08-10 | $0.00 derived: sum of 3 quarters · filed 2026-08-10 | $0.00 derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | $0.00 derived: sum of 3 quarters · filed 2026-05-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $0.00 derived: sum of 2 quarters · filed 2026-03-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-10 | $173.00K 10-K · filed 2026-03-04 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-10 | $173.00K 10-Q · filed 2025-11-05 | $384.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-10 | $173.00K 10-Q · filed 2026-08-10 | $384.00K derived: sum of 3 quarters · filed 2026-08-10 | $597.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $173.00K 10-Q · filed 2026-05-11 | $384.00K derived: sum of 2 quarters · filed 2026-05-11 | $597.00K derived: sum of 3 quarters · filed 2026-05-11 | $794.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $211.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $424.00K derived: sum of 2 quarters · filed 2026-03-04 | $621.00K derived: sum of 3 quarters · filed 2026-03-04 | $828.00K 10-K · filed 2026-03-04 |
| 2024-09-30 | $213.00K 10-Q · filed 2025-11-05 | $410.00K derived: sum of 2 quarters · filed 2025-11-05 | $617.00K 10-Q · filed 2025-11-05 | $837.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $197.00K 10-Q · filed 2025-08-13 | $403.00K 10-Q · filed 2025-08-13 | $624.00K derived: sum of 3 quarters · filed 2025-08-13 | $836.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $205.00K 10-Q · filed 2025-05-15 | $427.00K derived: sum of 2 quarters · filed 2025-05-15 | $639.00K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $434.00K derived: sum of 2 quarters · filed 2025-03-12 | $3.13M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $212.00K 10-Q · filed 2024-11-06 | $2.91M 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |